| Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ... New England Journal of Medicine 373 (8), 726-736, 2015 | 1882 | 2015 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1859 | 2020 |
| Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ... Journal of Clinical Oncology 36 (1), 7-13, 2018 | 818 | 2018 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 697 | 2020 |
| Efficacy of Selpercatinib in RET-Altered Thyroid Cancers LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ... New England Journal of Medicine 383 (9), 825-835, 2020 | 648 | 2020 |
| Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease C Fermé, H Eghbali, JH Meerwaldt, C Rieux, J Bosq, F Berger, T Girinsky, ... New England Journal of Medicine 357 (19), 1916-1927, 2007 | 563 | 2007 |
| Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial V Subbiah, U Lassen, E Élez, A Italiano, G Curigliano, M Javle, ... The Lancet Oncology 21 (9), 1234-1243, 2020 | 395 | 2020 |
| Precision Targeted Therapy with BLU-667 for RET-Driven Cancers V Subbiah, JF Gainor, R Rahal, JD Brubaker, JL Kim, M Maynard, W Hu, ... Cancer discovery 8 (7), 836-849, 2018 | 382 | 2018 |
| Vemurafenib for BRAF V600–mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study EL Diamond, V Subbiah, AC Lockhart, JY Blay, I Puzanov, I Chau, ... JAMA oncology 4 (3), 384-388, 2018 | 373 | 2018 |
| Selective RET kinase inhibition for patients with RET-altered cancers V Subbiah, V Velcheti, BB Tuch, K Ebata, NL Busaidy, ME Cabanillas, ... Annals of Oncology 29 (8), 1869-1876, 2018 | 369 | 2018 |
| Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial J Trigo, V Subbiah, B Besse, V Moreno, R López, MA Sala, S Peters, ... The lancet oncology 21 (5), 645-654, 2020 | 345 | 2020 |
| Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ... The lancet oncology 22 (7), 959-969, 2021 | 333 | 2021 |
| BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study T Kaley, M Touat, V Subbiah, A Hollebecque, J Rodon, AC Lockhart, ... Journal of Clinical Oncology 36 (35), 3477-3484, 2018 | 300 | 2018 |
| Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells C Tang, JW Welsh, P De Groot, E Massarelli, JY Chang, KR Hess, S Basu, ... Clinical Cancer Research 23 (6), 1388-1396, 2017 | 300 | 2017 |
| Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study V Subbiah, MI Hu, LJ Wirth, M Schuler, AS Mansfield, G Curigliano, ... The lancet Diabetes & endocrinology 9 (8), 491-501, 2021 | 267 | 2021 |
| Cancer therapy directed by comprehensive genomic profiling: a single center study JJ Wheler, F Janku, A Naing, Y Li, B Stephen, R Zinner, V Subbiah, S Fu, ... Cancer research 76 (13), 3690-3701, 2016 | 256 | 2016 |
| RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients S Kato, V Subbiah, E Marchlik, SK Elkin, JL Carter, R Kurzrock Clinical Cancer Research 23 (8), 1988-1997, 2017 | 251 | 2017 |
| Clinical development of BRAF plus MEK inhibitor combinations V Subbiah, C Baik, JM Kirkwood Trends in cancer 6 (9), 797-810, 2020 | 244 | 2020 |
| Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial PY Wen, A Stein, M van den Bent, J De Greve, A Wick, FYFL de Vos, ... The lancet oncology 23 (1), 53-64, 2022 | 228 | 2022 |
| Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, ... Cancer discovery 6 (12), 1352-1365, 2016 | 228 | 2016 |
